Results 51 to 60 of about 9,895 (222)
Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery [PDF]
, 2022 Minimizing in vitro and in vivo testing in early drug discovery with the use of physiologically based pharmacokinetic (PBPK) modeling and machine learning (ML) approaches has the potential to reduce discovery cycle times and animal experimentation ...
Andrés Olivares-Morales (12468640) +3 more
core +3 more sources
Physiology Based Pharmacokinetic (Pbpk) Model in Paediatric Drug Development [PDF]
, 2023 Purpose Physiologically based pharmacokinetic (PBPK) modelling, a mathematical modelling approach which uses a pharmacokinetic model to mimic human physiology to predict drug concentration–time profiles, has been used for the discover and development of ...
D.M. Ravichand, G Naveen choudary,
core
PLoS Computational Biology, 2016 Developing physiologically-based pharmacokinetic (PBPK) models for chemicals can be resource-intensive, as neither chemical-specific parameters nor in vivo pharmacokinetic data are easily available for model construction.
Jingtao Lu +12 more
doaj +1 more source
PRT to predict pharmacokinetic profiles as part of a bioequivalence study of the drug deferasirox
Разработка и регистрация лекарственных средствIntroduction. Deferasirox is a complexing drug and belongs to class II according to the biopharmaceutical classification system (BCS), has acidic properties and belongs to subclass “a” (acid).
A. V. Suvorova +6 more
doaj +1 more source
Adapting physiologically-based pharmacokinetic models for machine learning applications
Scientific Reports, 2023 Both machine learning and physiologically-based pharmacokinetic models are becoming essential components of the drug development process. Integrating the predictive capabilities of physiologically-based pharmacokinetic (PBPK) models within machine ...
Sohaib Habiballah, Brad Reisfeld
doaj +1 more source
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK [PDF]
CPT: Pharmacometrics & Systems Pharmacology, 2015 The US Food and Drug Administration (FDA) public workshop, entitled “Application of Physiologically‐based Pharmacokinetic (PBPK) Modeling to Support Dose Selection focused on the role of PBPK in drug development and regulation. Representatives from industry, academia, and regulatory agencies discussed the issues within plenary and panel discussions ...
Wagner, C +6 more
openaire +2 more sources
Autonomous AI‐Driven Design for Skin Product Formulations
Advanced Intelligent Discovery, EarlyView.This review presents a comprehensive closed‐loop framework for autonomous skin product formulation design. By integrating artificial intelligence‐driven experiment selection with automated multi‐tiered assays, the approach shifts development from trial‐and‐error to intelligent optimisation.
Yu Zhang +5 more
wiley +1 more source
Trends of PBPK literatures. [PDF]
, 2016 (A) The 2,039 PBPK-related articles are placed into one of three categories: (1) unique chemical PBPK papers (grey), pioneering articles in which specific chemical names have appeared for the first time; (2) non-unique chemical PBPK papers (yellow ...
Jingtao Lu (1806880) +12 more
core
, 2017 Simulated concentration-time curves (lines) for all parent drugs (blue) were assessed with experimental PK profiles (circles) used for developing reference (ref.) or validated (val.) human PBPK models.
Lorenzo Fabbri (3712408) +8 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis +5 more
wiley +1 more source